



## ASX ANNOUNCEMENT

14 February 2024

### Cann to present half year results webinar

---

**14 February 2024** – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) is pleased to invite shareholders, investors and interested parties to an investor update webinar and Q&A with CEO, Peter Koetsier.

The webinar will be held on **Wednesday, 28 February 2024** at **11:00 am** (Melbourne time).

For the Q&A session, investors are invited to send questions prior to the webinar, to [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

Register for the webinar at the following link:

[https://us02web.zoom.us/webinar/register/WN\\_KB3PcoKHRamEJw6F0liQNQ](https://us02web.zoom.us/webinar/register/WN_KB3PcoKHRamEJw6F0liQNQ)

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those that would prefer to join by phone.

A recording will be available at the above link shortly after the conclusion of the live session.

**Authorised for release by Steven Notaro, Company Secretary, Cann Group Limited.**

**For all media enquiries please contact:**

Jackson Paine  
Corporate Communications Manager  
+61 439 492 955  
[jackson.paine@canngrouponlimited.com](mailto:jackson.paine@canngrouponlimited.com)

**For all other information please contact:**

Peter Koetsier  
CEO  
Cann Group Limited  
+61 3 9095 7088  
[contact@canngrouponlimited.com](mailto:contact@canngrouponlimited.com)

Steven Notaro  
Head of Legal & Regulatory Affairs and  
Company Secretary  
Cann Group Limited  
+61 3 9095 7088  
[steven.notaro@canngrouponlimited.com](mailto:steven.notaro@canngrouponlimited.com)

**About Cann Group**

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology. **Learn more at:** [www.canngrouponlimited.com](http://www.canngrouponlimited.com) | [www.satipharm.com](http://www.satipharm.com)